Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
News|Articles|February 20, 2025
Social Media's Influence on Young Women's Reproductive Decisions
Author(s)Miranda Schmalfuhs
In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
Advertisement
Advertisement
Mis- and disinformation on social media is a growing concern for both pharmaceutical companies and patients alike. Distrust in the various different platforms leave patients looking for guidance from any "trusted source," regulated or not, and the consequences could be disastrous. Young adults are increasing looking to their online parasocial relationships for advice on many topics, including health and medical care. This is just one of many challenges that the spread of misinformation presents.
Related to this article
Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Advertisement
Advertisement